BackBlackRock Health Sciences Trust Overview
BlackRock Health Sciences Trust

BlackRock Health Sciences Trust Discounted Cash Flow

Is BME undervalued? Intrinsic value estimate stands at $1.2.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$1.23

Current Fair Value

$1.23
↓ 97.4% Downside

Overvalued by 97.4% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

BlackRock Health Sciences Trust (BME) FAQ

BlackRock Health Sciences Trust posts a DCF fair value of $1.2. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Markets price BME on many factors — sentiment, liquidity, and near-term news — while DCF focuses on long-run cash flows. The current fair-value estimate of $1.2 sits 97.4% below the live price. Large gaps can highlight opportunity or model risk; the charts on this page help you see how the estimate has moved over time.

Context for BME's DCF fair value usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BlackRock Health Sciences Trust's other metric pages and overview cover the third.